Research programme: Gastrointestinal disorder therapeutics - Enterome Bioscience/ Takeda

Drug Profile

Research programme: Gastrointestinal disorder therapeutics - Enterome Bioscience/ Takeda

Alternative Names: EB 120; EB 420

Latest Information Update: 28 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Enterome; Takeda
  • Class
  • Mechanism of Action Immunomodulators; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 06 Jan 2016 Enterome Bioscience and Takeda agree to co-develop therapeutics in France for Gastrointestinal disorders
  • 06 Jan 2016 Preclinical trials in Inflammatory bowel disease in France (unspecified route)
  • 06 Jan 2016 Preclinical trials in Ulcerative colitis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top